PCVX — Vaxcyte, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1649094 ·
Last close
$59.40
Market Cap
$9.40B
52W High
$90.75
52W Low
$42.40
ADV30
2,392,666
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -308,274,000 | -297,062,000 | 2,989,136,000 | 125,470,000 | 499,918,000 |
| Jun 2026 | 0 | — | -302,777,000 | -284,302,000 | 3,138,154,000 | 183,190,000 | 380,212,000 |
| Mar 2026 | 0 | — | -345,850,000 | -320,622,000 | 3,348,308,000 | 260,843,000 | 352,294,000 |
| Dec 2025 | 0 | — | -274,283,000 | -246,507,000 | 3,002,717,000 | 173,959,000 | 317,207,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-962,009,000
Investing CF
$200,205,000
Financing CF
$604,366,000
CapEx
$-32,750,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-7.82
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-3,056,933,000
Inventory
—
Receivables
—
ST Investments
$1,166,759,000
EBIT TTM
$-1,231,184,000
Pretax Income TTM
$-1,148,493,000
Interest Exp TTM
—
Analysts
10
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -923,675,000 | -766,628,000 | 3,002,717,000 | 317,207,000 | 2,685,510,000 | -655,577,000 |
| Dec 2024 | 0 | -569,546,000 | -463,927,000 | 3,511,318,000 | 205,499,000 | 3,305,819,000 | -452,627,000 |
| Dec 2023 | 0 | -393,041,000 | -402,266,000 | 1,407,917,000 | 167,449,000 | 1,240,468,000 | -296,790,000 |
| Dec 2022 | 0 | -209,261,000 | -223,485,000 | 1,006,178,000 | 52,565,000 | 953,613,000 | -170,597,000 |
TTM Snapshot
Revenues TTM
$108,075,000
NetIncome TTM
$-1,064,261,000
OpCashFlow TTM
—
Assets (Latest)
$3,138,154,000
Forward EPS
$-7.15
Max Pain — expiry 2026-12-18
max pain strike: $55.00 · spot: $58.52 · call oi: 16,154 · put oi: 43,620
Expected Move to 2026-12-18:
±$7.25
(12.39%) —
implied range
$51.27 –
$65.77
· ATM straddle on $60.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| KRYS | Krystal Biotech, Inc. | $8.85B | $298.55 | — |
| QGEN | QIAGEN N.V. | $10.27B | $49.75 | — |
| RGEN | REPLIGEN CORP | $10.30B | $162.18 | — |
| KYMR | Kymera Therapeutics, Inc. | $10.37B | $121.52 | — |
| HALO | HALOZYME THERAPEUTICS, INC. | $10.94B | $95.97 | — |
News headlines (Yahoo Finance, 1h cache)
3 High Growth Stocks With At Least 33% Earnings Growth
2026-11-09 23:17 · Yahoo
Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-04 21:05 · Yahoo
Wall Street Analysts See an 87.35% Upside in Vaxcyte (PCVX): Can the Stock Really Move This High?
2026-10-30 12:55 · Yahoo
Wall Street Analysts Think Vaxcyte (PCVX) Could Surge 75.6%: Read This Before Placing a Bet
2026-10-14 12:55 · Yahoo
Why Vaxcyte (PCVX) Is Getting Attention Again
2026-10-08 18:15 · Yahoo
Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
2026-10-07 02:48 · Yahoo
Biotech Stocks Tumble, With Recent Winners Moderna, Vaxcyte Among The Biggest Losers
2026-10-06 20:34 · Yahoo
As Expected: Vaxcyte Announces $1 Billion Stock and Convertible Raise a Day After Its Phase 3 Win (and Sinks 10%)
2026-10-06 15:31 · Yahoo
Vaxcyte VAX-31 pneumococcal vaccine phase 3 trial results
2026-10-06 12:44 · Yahoo
Vaxcyte’s VAX-31 Meets All Primary Endpoints in Pivotal Phase III OPUS-1 Trial
2026-10-06 02:02 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.